Search Videos and More
Document
Contraception in Patients With a History of Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of contraception I patients with a history of breast cancer.
Document
CDK4/6 Inhibitors after Progression on CDK4/6 Inhibitor in Patients With Hormone Receptor-Positive/HER2-negative Advanced Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings to discuss recommendations regarding the use of CDK4/6 inhibitors after progression on CDK4/6 inhibitor in patients with hormone receptor-positive/HER2-negativ
News
Dana-Farber Research News 05.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from April 1 through April 15.
News
Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study
Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer
News
Dana-Farber Research News 04.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 through March 31.
News
Dana-Farber Researchers Receive AACR 2025 Scientific Achievement Awards
Matthew Meyerson, MD, PhD, FAACR, Toni K. Choueiri, MD, and Alice T. Shaw, MD, PhD, have been selected by the American Association for Cancer Research (AACR) as recipients of 2025 Scientific Achievement Awards.
News
Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment
Medical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each other and together provide the evidence needed to change patient care.
News
Novel Genomic Screening Tool Enables Precision Reverse-Engineering of Genetic Programming in Cells
Collaborative research led by investigators at Dana-Farber/Boston Children's Cancer and Blood Disorders Center defines a novel approach to understanding how certain proteins called transcription factors determine which genetic programs will drive cell growth and maturation.
News
Dana-Farber Research News 04.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 1 through March 15.
News
FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research
FDA decision establishes cabozantinib as a standard of care treatment for patients with previously treated advanced neuroendocrine tumors
News
Potential Targeted Therapy for Pediatric Brain Cancer Identified by Dana-Farber/Boston Children's Team
An international team of clinical collaborators, led by physician scientists from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma.
News
AI Learns Genomic “Language” to Advance Cancer Treatment
The human genome is a sequence of Ts, Gs, Cs, and As that is about 3 billion letters long. And, says Bradley Bernstein, MD, PhD, chair of Dana-Farber’s Department of Cancer Biology, “there’s no dictionary or guide for reading it.”